Orphazyme AS (CHIX:ORPHAC) Total Receivables : kr38.56 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Total Receivables?

Orphazyme AS's Total Receivables for the quarter that ended in Jun. 2022 was kr38.56 Mil.

Orphazyme AS Total Receivables Historical Data

The historical data trend for Orphazyme AS's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Total Receivables Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Receivables

Get a 7-Day Free Trial

11.37

14.45

11.28

18.45

43.82

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Total Receivables	Get a 7-Day Free Trial									27.74	18.45	69.51	43.82	38.56

Orphazyme AS Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Orphazyme AS Total Receivables Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines